Sarcoma & GIST
News
HDAC inhibition may reverse anthracycline resistance in patients with sarcoma
Key clinical point: Despite prior exposure to multiple regimens, clinical benefit was observed in several patients with advanced solid tumors,...
News
FDA approves eribulin for advanced liposarcoma
Median overall survival was 15.6 vs. 8.4 months and median progression-free survival was 2.9 vs. 1.7 months in patients with liposarcoma treated...
News
IDH1 mutant inhibitor targets gliomas, chondrosarcomas
Key clinical point: AG-120 is a first-in-class inhibitor of IDH1 mutations that may drive oncogenesis. Major finding: 10 of 20 patients with...
Conference Coverage
Experimental LOXO-101 induces regression in several hard-to-treat cancers
Key clinical point:Inhibition of TRK gene fusion products is a novel strategy for treating cancer. Major finding: Three of three patients...
News
Adjuvant imatinib for 3 years better than 1 year in high-risk GIST
Key clinical point: Patients with high-risk GIST treated with adjuvant imatinib for 3 years had longer relapse-free survival (RFS) and overall...
News
Dose-intensive, multiagent regimen improves outcomes from low-risk rhabdomyosarcoma
Key clinical point: A dose-intensive, multiagent regimen including dose-compressed cycles of ifosfamide/etoposide and vincristine/doxorubicin/...
News
FDA approves trabectedin for some advanced soft tissue sarcomas
News
Trabectedin superior for advanced liposarcoma, leiomyosarcoma
Key clinical point: Trabectedin was superior to standard dacarbazine by most measures in advanced, refractory liposarcoma and leiomyosarcoma,...
News
Preop chemo feasible for high-risk soft-tissue sarcomas
Preoperative chemotherapy is feasible for high-risk localized soft-tissue sarcomas of the limbs or superficial trunk, even with concurrent...
Feature
Genomic oncology: moving beyond the tip of the iceberg
Conference Coverage
ASCO: Eribulin results ‘a giant step for sarcoma’
Key clinical point: Eribulin is the first drug shown in a clinical trial to offer a survival advantage over existing therapies for metastatic soft...